Answers are grounded in this paper and cite their sources.
Prospective study finds elevated serum bilirubin and transaminases in children with ALL undergoing chemotherapy, indicating potential hepatotoxicity.
Background: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with treatment protocols accruing survival rates over 90%. Hepatotoxicity induced by chemotherapy, however, is a significant problem during treatment protocols. This study aims to evaluate the effects of induction chemotherapy on liver function tests in children with ALL. Methods: This prospective study was conducted at the Paediatric Haematology and Oncology Unit of Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh. Thirty (30) children aged 0-15 years with ALL from January 2002 to August 2003. Liver function tests like serum bilirubin, ALT, AST, alkaline phosphatase, serum albumin, and prothrombin time were monitored regularly before and after induction chemotherapy, during high-dose methotrexate treatment, and during the maintenance phase. Results: There were 27 patients (90%) in the age group 2-10 years with a male predominance (60%). Clinical presentation indicated universal anorexia and fatigue (100%), fever (90%), and hepatomegaly (70%). After induction chemotherapy, elevated serum bilirubin increased from 6.7% to 16.7% of patients with increased ALT increased from 20% to 30%. During the phase of high-dose methotrexate, 30% of the patients had hyperbilirubinemia, and 70% had elevated ALT. Most of the parameters are normalized in maintenance therapy. Conclusion: Induction chemotherapy and high-dose methotrexate significantly affect liver function in children with ALL by transiently elevating bilirubin and transaminases. Monitoring is essential to identify early hepatotoxicity during treatment phases
No takes yet. Share an insight, caveat, or question.
Rahman et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: